HKBU's Herbal Development for Ulcerative Colitis Gains Approval
![HKBU's Herbal Development for Ulcerative Colitis Gains Approval](https://investorshangout.com/images/blog/ihnews-HKBU%27s%20Herbal%20Development%20for%20Ulcerative%20Colitis%20Gains%20Approval.jpg)
HKBU Develops Chinese Medicine for Ulcerative Colitis
The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong Kong Baptist University (HKBU) has reached a significant milestone with its innovative approach to treating ulcerative colitis. The team's recent success revolves around a novel Chinese herbal formulation aimed at maintaining remission in patients suffering from this challenging condition. After submitting an Investigational New Drug application for CDD-2103 to the National Medical Products Administration (NMPA), the centre celebrated its approval for clinical trials.
Clinical Trial Authorization Marks a Milestone
The approval from NMPA, received recently, facilitates the commencement of a Phase II clinical trial planned for next year to assess the safety and effectiveness of CDD-2103. This trailblazing step not only opens doors for more effective treatments but also reflects the centre's commitment to where tradition meets modern medicine.
Ulcerative Colitis and its Challenges
Ulcerative colitis is a type of inflammatory bowel disease known for its growing prevalence, especially in regions where traditional dietary habits might not support gut health. Patients often face debilitating symptoms such as diarrhea, rectal bleeding, and severe abdominal cramps, which significantly undermine their quality of life.
Classified into active and remission phases, managing ulcerative colitis is complex. Current treatment strategies often fall short, failing to maintain remission or prevent recurrence effectively. Driven by the need for better solutions, researchers at HKBU have crafted CDD-2103, combining several traditional Chinese herbal medicines, including Codonopsis Radix and Curcumae Longae Rhizoma. This blend aims to address specific symptoms associated with spleen deficiency and internal damp heat accumulation.
Research and Development of CDD-2103
A clinical trial conducted by the research team demonstrated that CDD-2103, administered in a decoction format, was well-tolerated by patients, showcasing no adverse effects. The team progressed to develop the CDD-2103 granule under NMPA's stringent quality control standards, completing essential preclinical studies.
Promising results showed that CDD-2103 actively suppressed the progression of colitis. It did this by promoting a tolerogenic immune microenvironment through the modulation of regulatory T-cell differentiation and diminishing the presence of inflammatory macrophages in the colon, which contributes to a healthier gut barrier. Studies have been documented in reputable journals such as Journal of Advanced Research and Journal of Ethnopharmacology.
Future Prospects and Expectations
Professor Bian Zhaoxiang, an essential figure behind this initiative, expressed optimism about the development's potential to uplift patients' quality of life. He emphasized that CDD-2103 represents a blend of modified ancient formulations and modern scientific approaches. The approval to carry out a Phase II clinical trial marks a critical recognition of the research team's efforts and dedication.
Focus on Safety and Efficacy
The upcoming randomised, double-blind, placebo-controlled trial in the Mainland will specifically evaluate the safety and effectiveness of CDD-2103 in patients experiencing remission. Dr. Tan Hor Yue, an assistant professor at CDD, indicated that the larger-scale trials anticipated in the coming years would provide necessary confirmation of CDD-2103's therapeutic effects.
The Role of CDD in Innovation
Located within the Hong Kong Science Park, CDD stands out as a unique centre dedicated solely to the research and development of Chinese herbal medicines at a local university. Since its inception in 2020, CDD has concentrated on innovative research tackling gastrointestinal and immune-related diseases, managing chronic constipation, and focusing on ulcerative colitis. This is made possible with funding support from the Innovation and Technology Commission's InnoHK initiative.
Frequently Asked Questions
What is CDD-2103?
CDD-2103 is a novel Chinese herbal formulation developed to maintain remission in ulcerative colitis patients.
Where has the clinical trial for CDD-2103 been approved?
The clinical trial has been approved by the National Medical Products Administration (NMPA).
What symptoms does ulcerative colitis cause?
Common symptoms include diarrhea, rectal bleeding, and abdominal cramps, which severely impact patients' quality of life.
How does CDD-2103 work?
CDD-2103 works by modulating the immune system to improve gut health and suppress inflammation in the colon.
What makes CDD unique?
CDD is the only centre in a local university focusing specifically on the development of Chinese herbal medicines, innovating for gastrointestinal and immune-related diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Global Net Lease Drives Strategic Asset Sales Forward
- Prospera Introduces IgniteProspera for Future Leaders' Growth
- PAM Health Announces Strategic Promotions for Growth
- Neo4j Unveils Enhanced Cloud Database for GenAI Adoption
- LegitScript and EMS Join Forces to Elevate Payment Security
- Lilly and EVA Pharma Join Forces to Enhance Baricitinib Access
- Reticulate Micro Launches VAST™ for Efficient Video Encoding
- SOPHiA GENETICS Launches Enhanced DDM Platform for Healthcare
- Way.com Teams Up with Sea Air FCU for Affordable Auto Loans
- Investing in Dividend Stocks: Opportunities for September Success
- MUV Rental Market Forecast: Growth to $14.4 Billion by 2032
- China Merchants Fund Management Reinforces Salary Limits for Staff
- Zscaler's Revenue Forecast Falls Short Amid Cybersecurity Challenges
- Digital Neuro Biomarkers Market Set for Major Growth by 2033
- Eckoh Plc Public Disclosure: Key Information and Dealings
- Amazon's AI Investments Position it for Future Growth
- Mr. Lid Launches New Lunch Bento Boxes for Back to School
- Simulators Market Forecast to Hit USD 36 Billion by 2032
- VIS and NXP Join Forces to Launch VSMC Semiconductor Venture
- Prompt Security Unveils Groundbreaking Governance Solution for Microsoft 365
- Barratt Developments Sees Profits Fall Amid Market Challenges
- Cloud Storage Market Growth Forecast Showcases Major Trends
- Remote Work Security Market Forecast: $322.6 Billion by 2032
- Amebocyte Lysate Market Forecast: Growth to $1.9 Billion
- Argus Launches New Prices for Heavy Canadian Crude Exports
Recent Articles
- Zscaler's Revenue Forecast Falls Short Amid Cybersecurity Challenges
- Zinzino AB Reports Robust August 2024 Sales Growth
- Global Burn Care Market Expected to Reach USD 4.88 Billion
- Ascendis Pharma Faces Stock Drop After Earnings Report
- Celebrate International Coffee Day with Julius Meinl's New Coffee
- Advancing China-Africa Cooperation for a Shared Future
- Japan's Motegi Proposes Stimulus for Economic Recovery
- Asian Markets React to Wall Street's August Decline
- Michelin Reports Own Share Trading for September Activity
- Sampo plc Announces Recent Share Buybacks and Updates
- Cipollone Highlights Risks of ECB's Restrictive Policies
- Revamping the Global Refurbished Smartphone Market Outlook
- Jazz Pharmaceuticals Pricing Strategy for $850 Million Notes
- Canacol Energy Secures $75 Million Loan to Enhance Operations
- Investigation Into AvidXchange Holdings, Inc. (NASDAQ: AVDX) Claims
- NVIDIA Stock Plummets as US Equity Futures Dwindle
- MediciNova's MN-166 Abstract Accepted for NEALS 2024 Meeting
- Milan Laser Hair Removal Supports Veterans Through Makeover Show
- Healthcare Realty Trust Strengthens Nuveen Partnership, $700M Raise
- Executive Shift at Element Fleet Management: Welcoming New CFO
- ARCpoint's Corporate Update: CRESSO Transaction Insights
- Zentalis Pharmaceuticals Grants Stock Options to New Employees
- Extreme Networks Faces Class Action Lawsuit Amidst Allegations
- Auburn University Empowers Rural Communities in Alabama
- Sutter Home Wine Proudly Supports Buffalo Bills for 2024 Season